AlloVir, Inc.
ALVRNASDAQHealthcare
$9.81
+$0.39(+4.14%)
Market Cap$49475362
P/E Ratio—
52W High$24.15
52W Low$7.96
AlloVir, Inc. (ALVR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALVR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.46
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
🔥 4-Quarter EPS Beat Streak
ALVR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 12, 2026 | — | -$0.46 | — | — | — | — |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$4.37 | -$0.92 | +79.0% | — | — | — |
| — Q4 FY2025 | Nov 10, 2025 | — | -$0.64 | — | — | — | — |
| — Q3 FY2025 | Aug 7, 2025 | — | -$0.61 | — | — | — | — |
| ◌ Q2 FY2025 | May 12, 2025 | — | — | — | — | — | — |
| ▲ Q1 FY2025 | Mar 7, 2025 | -$2.76 | -$0.16 | +94.3% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$3.22 | -$0.92 | +71.4% | — | — | — |
| ▲ Q3 FY2024 | Aug 9, 2024 | -$2.30 | -$1.15 | +50.0% | — | — | — |
Q2 FY2026
May 12, 2026
EPS Actual
-$0.46
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
-$0.92
EPS Est.
-$4.37
EPS Surpr.
+79.0%
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
-$0.64
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 7, 2025
EPS Actual
-$0.61
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 7, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$2.76
EPS Surpr.
+94.3%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.92
EPS Est.
-$3.22
EPS Surpr.
+71.4%
Revenue
—
Q3 FY2024
Aug 9, 2024Beat
EPS Actual
-$1.15
EPS Est.
-$2.30
EPS Surpr.
+50.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-4.37 | $-4.37 | $-4.37 | 1 |
| Q4 FY2024 | $-2.76 | $-2.76 | $-2.76 | 1 |
| Q3 FY2024 | $-2.19 | $-2.19 | $-2.19 | 1 |
| Q2 FY2024 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 12, 2026 | — | $9.81 | — | — |
| ▲ Q1 FY2026 | Mar 17, 2026 | +79.0% | $9.81 | — | — |
| — Q4 FY2025 | Nov 10, 2025 | — | $9.81 | — | — |
| — Q3 FY2025 | Aug 7, 2025 | — | $9.81 | — | — |
| ▲ Q1 FY2025 | Mar 7, 2025 | +94.3% | $9.73 | $9.87 | +1.44% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +71.4% | $17.00 | $12.45 | -26.76% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +50.0% | $16.91 | $16.69 | -1.30% |
| ▼ Q2 FY2024 | May 13, 2024 | -12.5% | $18.07 | $17.25 | -4.54% |
Q2 FY2026—
Report Date
May 12, 2026
EPS Beat/Miss
—
Price Before
$9.81
Price After
—
Q1 FY2026—
Report Date
Mar 17, 2026
EPS Beat/Miss
+79.0%
Price Before
$9.81
Price After
—
Q4 FY2025—
Report Date
Nov 10, 2025
EPS Beat/Miss
—
Price Before
$9.81
Price After
—
Q3 FY2025—
Report Date
Aug 7, 2025
EPS Beat/Miss
—
Price Before
$9.81
Price After
—
Q1 FY2025+1.44%
Report Date
Mar 7, 2025
EPS Beat/Miss
+94.3%
Price Before
$9.73
Price After
$9.87
Q4 FY2024-26.76%
Report Date
Nov 12, 2024
EPS Beat/Miss
+71.4%
Price Before
$17.00
Price After
$12.45
Q3 FY2024-1.30%
Report Date
Aug 9, 2024
EPS Beat/Miss
+50.0%
Price Before
$16.91
Price After
$16.69
Q2 FY2024-4.54%
Report Date
May 13, 2024
EPS Beat/Miss
-12.5%
Price Before
$18.07
Price After
$17.25
Avg Beat Reaction-8.87%
Avg Miss Reaction-4.54%
Beat Rate4 / 8 quarters
Largest Move-26.76% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALVR ends December
AlloVir, Inc. (ALVR) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.46 (in line with the analyst consensus of —). ALVR has beaten EPS estimates for 4 consecutive quarters. The next ALVR earnings date is expected around September 1, 2026.
Each quarter, investors track ALVR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALVR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALVR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALVR earnings · 4 questionsAlloVir, Inc.'s next earnings report is expected around September 1, 2026. ALVR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALVR historically reports after market close (AMC).
ALVR earnings datewhen is ALVR earningsALVR next earnings datewhen does ALVR report earningsALVR earnings calendar
▸ Source: FMP · AlloVir, Inc. SEC filings · US GAAP · AlloVir, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026